Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUMELEIA study in frontline primary plasma cell leukemia
2024-518263-35-00Phase 2Authorised
- Sponsor
- Hellenic Society of Hematology
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, bortezomib, cyclophosphamide, doxorubicin and dexamethasone in plasma cell leukaemia (PCL), sponsored by Hellenic Society of Hematology. Primary endpoint: Progression-free survival. Planned start Nov 2021; status: authorised.
02
Drugs
daratumumabbortezomibcyclophosphamidedoxorubicindexamethasone
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on 2024-518263-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518263-35-00.